Going Too Fast

A recent clinical trial for a cancer immunotherapy drug from the biotech company Incyte failed, surprising many observers. Since then, a new editorial in Science notes, three companies have canceled, suspended, or downsized 12 other phase III trials of the compound, epacadostat, or two similar drugs. The compounds were designed to block an enzyme called indoleamine (2,3)- dioxygenase (IDO), and therefore turn the immune system on cancer cells.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Chinese state news agency Xinhua reports that a preliminary investigation has found He Jiankui performed his gene-editing work illegally.

John Mendelsohn, a former president of the University of Texas MD Anderson Cancer Center, has died, the New York Times reports.

Identical twins receive different estimates of ancestry from the same direct-to-consumer genetic testing firms, CBC reports.

In PNAS this week: chromosomal features of maize, adaptations in the vinous-throated parrotbill, and more.